The Yale SPORE in Skin Cancer program is focused on two skin cancers, basal cell carcinoma (BCC) and melanoma. The goals are to conduct epidemiologic and genetic studies on early onset basal cell carcinoma (Project 1), establish novel high-throughput prognostic and diagnostic tools for melanomas (Projects 2 and 4), and introduce novel targeted therapies to treat melanoma (Projects 2 and 3). The new approaches include genome-wide monitoring of melanoma tumor responses to epigenetic modifiers (Project 2); the use of high-density protein microarrays (ProtoArrays) to interrogate serological responses in sera from melanoma patients (Project 4); and novel epigenetic modifier and immune modulation therapy for melanoma (Projects 2 and 3, respectively). The SPORE includes Administration, Specimen Resource and Bioinformatics/Biostatistics Cores to support the studies of SPORE investigators. Developmental Research and Career Development Award Programs are proposed. The Yale SPORE in Skin Cancer will be an integral part of the Yale Comprehensive Cancer Center (YCCC), Yale New Haven Hospital, and the Dermatology, Pathology and Epidemiology/Public Health Departments that collectively will provide the patient populations, specimens and other resources and support systems needed for the SPORE activities. There is a full commitment from the Dean of Yale School of Medicine and the Director of the YCCC/Chairman of Dermatology to support the SPORE with a plan for cost sharing. The major Translational Results expected are: a) Guidelines for preventive interventions aimed at reducing the incidence of early and total BCC that will diminish the management costs of the most common skin cancer; b) The introduction of new molecular tools for assessing responses to novel epigenetic modifiers; c) The introduction of new ways of assessing melanoma patients employing serological markers; d) The application of new approaches to personalize melanoma chemo- and immuno- therapy; e) The establishment of a composite databases for skin cancers that includes specimens tracking, clinical information, high throughput proteomics and genomics. The database program will be compatible with caBIG and will be available on the web for the benefit of the wider community of investigators and clinicians; f) The creation of new translational bioinformatics tools (predictive statistics and artificial intelligence) required to analyze global and highly complex information derived from different sources and different platforms.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA121974-03
Application #
7664625
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
3
Fiscal Year
2008
Total Cost
$119,235
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Ferrucci, Leah M; Cartmel, Brenda; Clare, Rachel A et al. (2018) Cross-sectional assessment of ultraviolet radiation-related behaviors among young people after a diagnosis of melanoma or basal cell carcinoma. J Am Acad Dermatol 79:149-152
Arbesman, Joshua; Ravichandran, Sairekha; Funchain, Pauline et al. (2018) Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalanemia mutations. Pigment Cell Melanoma Res 31:529-533
Perry, Curtis J; Muñoz-Rojas, Andrés R; Meeth, Katrina M et al. (2018) Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J Exp Med 215:877-893
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Sulkowski, Parker L; Scanlon, Susan E; Oeck, Sebastian et al. (2018) PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF. Mol Cancer Res 16:1241-1254
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Krauthammer, Michael (2018) Unraveling the etiology of primary malignant melanoma of the esophagus. J Thorac Dis 10:S1074-S1075
Das, Rituparna; Bar, Noffar; Ferreira, Michelle et al. (2018) Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest 128:715-720
Miller, Chad J; Muftuoglu, Yagmur; Turk, Benjamin E (2017) A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases. Biochem Pharmacol 142:39-45
Kluger, Harriet M; Zito, Christopher R; Turcu, Gabriela et al. (2017) PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clin Cancer Res 23:4270-4279

Showing the most recent 10 out of 172 publications